Back to News
Market Impact: 0.2
Biohaven Consensus Price Target Increased 10.16% to $24.48
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The average one-year analyst price target for Biohaven (NYSE:BHVN) was revised up 10.16% to $24.48 per share from $22.22, based on aggregate targets collected as of October 30, 2026. The article does not report a share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
BHVN0.30
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Why is Apple stock falling afterhours today?